Neogenomics (NEO) Total Liabilities (2010 - 2026)

Neogenomics has reported Total Liabilities for 17 years, with the latest figure at $517.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 27.4% year-over-year to $517.8 million; the trailing twelve-month figure through Mar 2026 stood at $517.8 million (down 27.4% YoY), and the FY2025 full-year result was $523.3 million, down 28.87% from the prior year.
• Total Liabilities for Q1 2026 stood at $517.8 million, down from $523.3 million in the prior quarter.
• The five-year high for Total Liabilities was $754.5 million in Q1 2022, with the low at $517.8 million in Q1 2026.
• Historically, Total Liabilities has averaged $686.8 million across 5 years, with a median of $732.9 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities advanced 15.96% — and 2025, when it dropped 28.87%.
• Neogenomics' Total Liabilities stood at $742.0 million in 2022, then fell by 0.31% to $739.7 million in 2023, then declined by 0.54% to $735.7 million in 2024, then retreated by 28.87% to $523.3 million in 2025, then decreased by 1.05% to $517.8 million in 2026.
• The last three Total Liabilities figures came in at $517.8 million (Q1 2026), $523.3 million (Q4 2025), and $536.5 million (Q3 2025), per Business Quant data.